The DOI matches its Crossref record; 228 of the 231 references it cites were found in a registry or an index.
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Open accessAbstract
The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect non-obese insulin-resistant individuals. NAFLD is associated with a 2- to 3-fold increased risk of developing type 2 diabetes (T2D), which may be higher in patients with more severe liver disease - fibrosis increases this risk. In NAFLD, not only the close association with obesity, but also the impairment of many metabolic pathways, including decreased hepatic insulin sensitivity and insulin secretion, increase the risk of developing T2D and related comorbidities. Conversely, patients with diabetes have a higher prevalence of steatohepatitis, liver fibrosis and end-stage liver disease. Genetics and mechanisms involving dysfunctional adipose tissue, lipotoxicity and glucotoxicity appear to play a role. In this review, we discuss the altered pathophysiological mechanisms that underlie the development of T2D in NAFLD and vice versa. Although there is no approved therapy for the treatment of NASH, we discuss pharmacological agents currently available to treat T2D that could potentially be useful for the management of NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which however could be part of the therapeutic action (lipid partitioning with the expansion of subcutaneous adipose tissue) [36].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–228 of 228
Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice
Yamamoto, T. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i8.2512 · Cited by 48
Portillo-Sánchez, P., Bril, F., Lomonaco, R., Barb, D., Orsak, B., Bruder, J., & Cusi, K. J. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12833 · Cited by 44
Self-citationCusi, K. J., Sanyal, A. J., Zhang, S., Hoogwerf, B. J., Chang, A. M., Jacober, S. J., Bue-Valleskey, J. M., Higdon, A. N., Bastyr, E. J., Haupt, A., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12751 · Cited by 40
Self-citationPark, J. H., Lemieux, S., Lewis, G. F., Kuksis, A., & Steiner, G. A. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30037-7 · Cited by 39
Takeda, A., Irahara, A., Nakano, A., Takata, E., Koketsu, Y., Kimata, K., Senda, E., Yamada, H., Ichikawa, K., Fujimori, T., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8754-16 · Cited by 37
Arase, Y., Kawamura, Y., Seko, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Sezaki, H., Saito, S., et al. (2013) · Hepatology Research · doi:10.1111/hepr.12077 · Cited by 34
Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?
Gastaldelli, A., & Marchesini, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.031 · Cited by 34
Self-citationDPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
Sugimoto, T. (2014) · Medical Science Monitor · doi:10.12659/msm.890989 · Cited by 33
Bando, Y., Ogawa, A., Ishikura, K., Kanehara, H., Hisada, A., Notumata, K., Okafuji, K., & Toya, D. (2017) · Diabetology International · doi:10.1007/s13340-016-0302-y · Cited by 33
MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis inob/obmice
Ohyama, T., Sato, K., Yamazaki, Y., Hashizume, H., Horiguchi, N., Kakizaki, S., Mori, M., Kusano, M., & Yamada, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16227 · Cited by 31
Savvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30
Li, H., Rong-juan, X., Peng, X., Wang, Y., & Wang, T. (2013) · Molecular Biology Reports · doi:10.1007/s11033-012-2470-6 · Cited by 29
Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats
Tanaka, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2653 · Cited by 29
Rajagopalan, S., Dutta, P. R., Hota, D., Bhansali, A. K., Srinivasan, A., & Chakrabarti, A. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.030 · Cited by 27
Yabiku, K., Mutoh, A., Miyagi, K., & Takasu, N. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.015 · Cited by 27
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · Hepatology · doi:10.1002/hep.28960 · Cited by 26
Asakawa, M., Mitsui, H., Akihisa, M., Sekine, T., Niitsu, Y., Kobayashi, A., Miyake, A., Hashimoto, N., Kawamura, M., & Ogawa, Y. (2015) · SpringerPlus · doi:10.1186/s40064-015-1135-z · Cited by 24
Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models
Kim, M.-K., Chae, Y., Ahn, G.-J., Shin, C. Y., Choi, S., Yang, E. K., Sohn, Y. S., & Son, M.-H. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0864-z · Cited by 24
Camastra, S., Astiarraga, B., Tura, A., Frascerra, S., Ciociaro, D., Mari, A., Gastaldelli, A., & Ferrannini, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12836 · Cited by 23
Self-citationAdipose tissue insulin resistance in adolescents with and without type 2 diabetes
Kelsey, M. M., Forster, J. E., Pelt, R. E. V., Reusch, J. E. B., & Nadeau, K. J. (2013) · Pediatric Obesity · doi:10.1111/j.2047-6310.2013.00189.x · Cited by 22
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity
Soni, H. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.08.005 · Cited by 22
Wiggins, D. K., Hems, R., & Gibbons, G. F. (1995) · Metabolism · doi:10.1016/0026-0495(95)90235-x · Cited by 22
Nakamura, K., Fukunishi, S., Yokohama, K., Ohama, H., Tsuchimoto, Y., Asai, A., Tsuda, Y., & Higuchi, K. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2899 · Cited by 21
Grasselli, E., Voci, A., Demori, I., de Matteis, R., Compalati, A. D., Gallo, G., & Vergani, L. (2014) · Journal of physiology and biochemistry · doi:10.1007/s13105-013-0308-x · Cited by 16
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice
Choi, S. H., Leem, J., Park, S., Lee, C.-K., Park, K., & Lee, I. (2016) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2016-0026 · Cited by 15
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients
Kosi‐Trebotic, L., Thomas, A., Harreiter, J., Chmelík, M., Trattnig, S., & Kautzky‐Willer, A. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12817 · Cited by 14
Pharmacological Differences of Glitazones
Kintscher, U. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.012 · Cited by 10
Global Health Perspectives in Prediabetes and Diabetes Prevention
Bergman, M. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9170 · Cited by 8
Flagged first, then by citations
3 of the 231 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Gastaldelli, 2014, Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?, Volume 1, 31
Cited by
Sorted by citations
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationCusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationA Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2036205 · Cited by 801
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Quek, J., Chan, K. E., Wong, Z. Y., Tan, C., Tan, B., Lim, W. H., Tan, D. J. H., Tang, A. S. P., Tay, P., Xiao, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00317-x · Cited by 749
Metadata
- Authors
- Gastaldelli, A., & Cusi, K.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- University of Florida (US)
- Corresponding author
- Gastaldelli, Amalia
- Cusi, Kenneth
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 1
- Issue
- 4
- Pages
- 312-328
- ISSN
- 2589-5559 (ISSN-L)
- PMC
- PMC7001557
- OpenAlex
- W2963543751
- Cited by
- 455
- References
- 231
- Citations by year
- 2026: 48 · 2025: 69 · 2024: 85 · 2023: 74 · 2022: 62 · 2021: 78 · 2020: 34 · 2019: 3
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JHEP Reports (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Horizon H2020 (634413)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, insulin resistance, hepatic insulin sensitivity, insulin secretion, liver fibrosis, end-stage liver disease, lipotoxicity, glucotoxicity, adipose tissue dysfunction, obesity, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
